Shire

Shire
Share

Shire

 •  February 20

Hereditary angioedema (HAE) and primary immunodeficiency (PI) data to be presented,
including results from pivotal Phase 3 HELP™ study exploring investigational
lanadelumab as a preventative treatment for HAE CAMBRIDGE, Mass. – February 20, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced...

Shire

 •  February 15

FDA assigns an action date of June 20, 2018 If approved, CINRYZE will be the first and only C1-INH therapy indicated to help prevent HAE attacks from childhood into adulthood Shire is the only HAE drug developer to complete pediatric studies for the prophylactic treatment of HAE CAMBRIDGE, MA – February 15, 2018 – Shire plc (LSE: SHP, NASDAQ:...

Shire

 •  February 5

12 presentations and three satellite symposia showcase Shire’s commitment to improving understanding and treatment of these life-altering disorders Cambridge, Ma. – February 5, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters and...

Shire

 •  January 30

AB Biosciences to Receive an Upfront License Fee and Potential Research, Development and Commercial Milestone Payments from Shire Shire Receives Exclusive Worldwide License to Develop and Commercialize PRIM Program Allston, Mass., and Cambridge, Mass, January 30, 2018 – AB Biosciences, Inc. and Shire plc (LSE: SHP, NASDAQ: SHPG), the global...

Shire

 •  January 24

Second production source for Cinryze drug product strengthens Shire’s ability
to meet growing patient demand Dublin, Ireland – January 24, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the U.S. Food and Drug Administration has granted approval for the technology transfer of...

Shire

 •  January 22

Cambridge, Mass. – January 22, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that data will be presented on GATTEX® / REVESTIVE®▼ (teduglutide [rDNA origin]) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support (PS)1,2 at the ASPEN...

Shire

 •  January 15

Marketing Authorization will enable patient access to ADYNOVI throughout Europe Zug, Switzerland – January 15, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant),...

Shire

 •  December 27, 2017

Dublin, Ireland – December 27, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that it has filed its first submission to the United States Food and Drug Administration for the company’s new plasma manufacturing facility in Covington, Georgia. The facility is expected to add approximately...

Shire

 •  December 19, 2017

First and only FDA-cleared PK dosing software to support healthcare professionals in creating personalized dosing regimens for patients 16 and older with hemophilia A1 myPKFiT for ADVATE software availability planned for end of Q1 2018 Cambridge, Ma. – December 19, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare...

Shire

 •  December 19, 2017

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced top-line results from its Phase II/III clinical trial evaluating SHP609, previously known as HGT-2310. SHP609 is an investigational formulation of idursulfase administered intrathecally for a new potential indication for the treatment of pediatric patients...